Journal Issue: Br J Cancer Volume 131(3);  2024 Aug 24

Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Journal List

Volume 131(3);  2024 Aug 24

Review Articles

Metastasis-associated fibroblasts in peritoneal surface malignancies
Cristiano Ramos, Vasileios Gerakopoulos, Rudolf Oehler
Br J Cancer. 2024 Aug 24; 131(3): 407–419. Published online 2024 May 23. doi: 10.1038/s41416-024-02717-4
PMCID:
PMC11300623
Abstract Article PDF–1000K
The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications
Kaina Chen, Timothy W. H. Shuen, Pierce K. H. Chow
Br J Cancer. 2024 Aug 24; 131(3): 420–429. Published online 2024 May 17. doi: 10.1038/s41416-024-02684-w
PMCID:
PMC11300599
Abstract Article PDF–1.1M

Articles

CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Xinlin Liu, Wei Li, Lu Yi, Jianxi Wang, Wentao Liu, Hongtao Cheng, Shangqing Ren
Br J Cancer. 2024 Aug 24; 131(3): 444–456. Published online 2024 Jun 18. doi: 10.1038/s41416-024-02750-3
PMCID:
PMC11300639
Abstract Article PDF–3.8M
The in vitro dynamics of pseudo-vascular network formation
Mariam-Eleni Oraiopoulou, Dominique-Laurent Couturier, Ellie V. Bunce, Ian G. Cannell, Paul W. Sweeney, Huw Naylor, Monika Golinska, Gregory J. Hannon, Vangelis Sakkalis, Sarah E. Bohndiek
Br J Cancer. 2024 Aug 24; 131(3): 457–467. Published online 2024 Jun 20. doi: 10.1038/s41416-024-02722-7
PMCID:
PMC11300916
Abstract Article PDF–3.1M
Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation
David Schörghofer, Laurenz Vock, Madalina A. Mirea, Oliver Eckel, Anna Gschwendtner, Jürgen Neesen, Erika Richtig, Markus Hengstschläger, Mario Mikula
Br J Cancer. 2024 Aug 24; 131(3): 468–480. Published online 2024 Jun 20. doi: 10.1038/s41416-024-02758-9
PMCID:
PMC11300789
Abstract Article PDF–3.7M
Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer
Judith L. Gulikers, Leila-Sophie Otten, Lizza E. L. Hendriks, Kristien Winckers, Yvonne Henskens, Jenneke Leentjens, Michel M. van den Heuvel, Rob ter Heine, Sander Croes, Berber Piet, Robin M. J. M. van Geel
Br J Cancer. 2024 Aug 24; 131(3): 481–490. Published online 2024 Jun 11. doi: 10.1038/s41416-024-02744-1
PMCID:
PMC11300802
Abstract Article PDF–1.1M
Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom
Gerard C. Millen, Alice Lawford, Catriona Duncan, Helen Jenkinson, Gareth J. Veal, Shelby Barnett
Br J Cancer. 2024 Aug 24; 131(3): 491–497. Published online 2024 Jun 13. doi: 10.1038/s41416-024-02728-1
PMCID:
PMC11300439
Abstract Article PDF–373K
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review
Tsun Ho Chan, J. Eunice Zhang, Munir Pirmohamed
Br J Cancer. 2024 Aug 24; 131(3): 498–514. Published online 2024 Jun 17. doi: 10.1038/s41416-024-02754-z
PMCID:
PMC11300675
Abstract Article PDF–612K
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition
Sophie Merrick, Hannah L. Rush, Susanna Daniels, Alison Fielding, Sharon Deveson Kell, Lisa Pickering, Ruth E. Langley, Annabelle South, Duncan C. Gilbert
Br J Cancer. 2024 Aug 24; 131(3): 515–523. Published online 2024 Jun 17. doi: 10.1038/s41416-024-02756-x
PMCID:
PMC7616340
Abstract Article PDF–423K
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
Jan Budczies, Eva Romanovsky, Martina Kirchner, Olaf Neumann, Miriam Blasi, Johannes Schnorbach, Rajiv Shah, Farastuk Bozorgmehr, Rajkumar Savai, Thorsten Stiewe, Solange Peters, Peter Schirmacher, Michael Thomas, Daniel Kazdal, Petros Christopoulos, Albrecht Stenzinger
Br J Cancer. 2024 Aug 24; 131(3): 524–533. Published online 2024 Jun 12. doi: 10.1038/s41416-024-02746-z
PMCID:
PMC11300455
Abstract Article PDF–840K
Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response
Amy L. Nagelberg, Tianna S. Sihota, Yu-Chi Chuang, Rocky Shi, Justine L. M. Chow, John English, Calum MacAulay, Stephen Lam, Wan L. Lam, William W. Lockwood
Br J Cancer. 2024 Aug 24; 131(3): 534–550. Published online 2024 Jun 18. doi: 10.1038/s41416-024-02755-y
PMCID:
PMC11300780
Abstract Article PDF–1.6M
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina, Michelle de Marchena, Supipi Auwardt, Shaza Sayed Ahmed, Nicole Virginia Bremer, Soo-Ryum Yang, Yangbo Feng, Chao Zhou, Norman Kong, Ruixia Liang, Haipeng Xu, Bin Zhang, Alberto Bardelli, Eneda Toska, Andrea Ventura, Alexander Drilon, Emiliano Cocco
Br J Cancer. 2024 Aug 24; 131(3): 601–610. Published online 2024 Jun 20. doi: 10.1038/s41416-024-02760-1
PMCID:
PMC11300601
Abstract Article PDF–1.5M

Editorial Expression of Concern

Editorial Expression of Concern: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential
S. Khan, J. R. Aspe, M. G. Asumen, F. Almaguel, O. Odumosu, S. Acevedo-Martinez, M. De Leon, W. H. R. Langridge, N. R. Wall
Br J Cancer. 2024 Aug 24; 131(3): 614. Published online 2024 Jul 16. doi: 10.1038/s41416-024-02793-6
Expression of Concern about:
Br J Cancer. 2009 Apr 7; 100(7): 1073–1086.
PMCID:
PMC11300783
Article PDF–146K

Corrections

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Cornelius F. Waller, Julia Möbius, Adolfo Fuentes-Alburo
Br J Cancer. 2024 Aug 24; 131(3): 611. Published online 2024 Jul 3. doi: 10.1038/s41416-024-02769-6
Corrects:
Br J Cancer. 2021 Apr 12; 124(8): 1346–1352.
PMCID:
PMC11300457
Correction PDF–213K
Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer
Pingfu Hou, Peicong Shi, Tao Jiang, Hang Yin, Sufang Chu, Meilin Shi, Jin Bai, Jun Song
Br J Cancer. 2024 Aug 24; 131(3): 612–613. Published online 2024 Jul 17. doi: 10.1038/s41416-024-02801-9
Corrects:
Br J Cancer. 2020 Mar 3; 122(5): 668–679.
PMCID:
PMC11300866
Correction PDF–597K
Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK